FDA to delay decision on Eli Lilly Alzheimer's drug for second time
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Recent Alzheimer's disease dynamics are a positive for Biogen's Leqembi - analyst
March 11, 2024 2:01 PM EDTOn Monday, Oppenheimer reiterated its Outperform rating and $290 price target for Biogen (NASDAQ: BIIB) amid recent developments in the Alzheimer's Disease (AD) treatment landscape. The competitive dynamics have shifted significantly, potentially benefiting Biogen's AD drug, Leqembi, which is developed in partnership with Eisai. Eisai has reported progress on multiple fronts for Leqembi, while a competitor, Eli Lilly, announced an unexpected delay for its AD drug,... More
